Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APEN Apollo Endosurgery		$9.94	$3.49 ▼ $10.30	$579.72M	2.31	1.43 million shs	1.66 million shs
BVS Bioventus	$6.44 +2.2%	$6.69	$6.02 ▼ $14.38	$529.01M	0.84	429,906 shs	467,995 shs
CATX Perspective Therapeutics	$4.30 -0.2%	$3.25	$1.60 ▼ $16.55	$319.18M	1.18	1.09 million shs	841,943 shs
INFU InfuSystem	$5.75 +4.4%	$5.95	$4.61 ▼ $9.97	$120.84M	1.81	117,716 shs	144,781 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APEN Apollo Endosurgery	0.00%	0.00%	0.00%	0.00%	0.00%
BVS Bioventus	+0.64%	-7.49%	-3.82%	-15.89%	-12.13%
CATX Perspective Therapeutics	+2.62%	+7.75%	+24.57%	+101.40%	-65.90%
INFU InfuSystem	+0.55%	-1.78%	-11.84%	+14.79%	-19.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APEN Apollo Endosurgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	3.066 of 5 stars	3.4	0.0	0.0	0.0	1.9	3.3	1.3
CATX Perspective Therapeutics	2.3925 of 5 stars	4.6	1.0	0.0	0.0	1.9	0.8	0.0
INFU InfuSystem	3.3402 of 5 stars	2.0	5.0	0.0	0.0	0.0	4.2	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APEN Apollo Endosurgery	0.00	N/A	N/A	N/A
BVS Bioventus	2.75	Moderate Buy	$13.75	112.85% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	190.97% Upside
INFU InfuSystem	3.67	Strong Buy	$12.50	119.88% Upside

Current Analyst Ratings Breakdown

Latest APEN, BVS, CATX, and INFU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
5/8/2025	INFU InfuSystem	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APEN Apollo Endosurgery	$76.86M	0.00	N/A	N/A	$0.69 per share	0.00
BVS Bioventus	$567.70M	0.93	$0.51 per share	12.58	$2.80 per share	2.31
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
INFU InfuSystem	$137.58M	0.87	$0.44 per share	12.79	$2.47 per share	2.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APEN Apollo Endosurgery	-$39.84M	-$1.02	N/A	N/A	N/A	-51.84%	-89.48%	-33.76%	N/A
BVS Bioventus	-$156.23M	-$0.48	N/A	14.04	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/13/2025 (Estimated)
INFU InfuSystem	$870K	$0.14	94.77	18.34	N/A	1.12%	2.78%	1.41%	N/A

Latest APEN, BVS, CATX, and INFU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	N/A	CATX Perspective Therapeutics	-$0.30	N/A	N/A	N/A	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APEN Apollo Endosurgery	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APEN Apollo Endosurgery	1.04	2.35	1.89
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
INFU InfuSystem	0.50	1.98	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APEN Apollo Endosurgery	76.01%
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
INFU InfuSystem	71.13%

Insider Ownership

Company	Insider Ownership
APEN Apollo Endosurgery	17.30%
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.72%
INFU InfuSystem	11.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APEN Apollo Endosurgery	202	57.97 million	47.94 million	Not Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
INFU InfuSystem	410	21.02 million	19.10 million	Optionable

APEN, BVS, CATX, and INFU Headlines

Recent News About These Companies

InfuSystem (NYSE:INFU) Earns Buy Rating from Analysts at Roth Capital

July 22 at 10:36 AM | marketbeat.com

InfuSystem (NYSE:INFU) Stock Price Up 2.6% - Here's Why

July 10, 2025 | marketbeat.com

InfuSystem, Apollo Medical Supply join forces

June 24, 2025 | hmenews.comH

InfuSystem: Investments Are Starting To Pay Off

June 22, 2025 | seekingalpha.com

InfuSystem Holdings, Inc. (NYSE:INFU) Director Acquires $10,360.00 in Stock

May 29, 2025 | insidertrades.com

Insider Buying: InfuSystem Holdings, Inc. (NYSE:INFU) COO Buys 1,967 Shares of Stock

May 20, 2025 | insidertrades.com

Barry G. Steele Acquires 3,000 Shares of InfuSystem Holdings, Inc. (NYSE:INFU) Stock

May 16, 2025 | insidertrades.com

InfuSystem positioned for ‘successful year’

May 12, 2025 | hmenews.comH

InfuSystem Holdings, Inc. (INFU) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Earnings call transcript: InfuSystem Q1 2025 sees stock surge despite EPS miss

May 10, 2025 | uk.investing.com

InfuSystem Holdings, Inc. (AMEX:INFU) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

InfuSystem Holdings, Inc. Reports Strong Q1 2025 Performance

May 8, 2025 | tipranks.com

InfuSystem Reports First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

InfuSystems Holdings, Inc. (INFU) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025 | businesswire.com

InfuSystem’s Dilorio to step down in May

April 2, 2025 | hmenews.comH

InfuSystem CEO stepping down May 19, COO Carrie Lachance succeeds

April 2, 2025 | markets.businessinsider.com

Lake Street Initiates a Buy Rating on InfuSystem Holdings, Inc. (INFU)

April 1, 2025 | markets.businessinsider.com

Rochester Hills medical device company selects new CEO

April 1, 2025 | crainsdetroit.comC

InfuSystem still sees 2025 revenue growth 8%-10% from $134.86M in 2024

April 1, 2025 | markets.businessinsider.com

InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

April 1, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APEN, BVS, CATX, and INFU Company Descriptions

Apollo Endosurgery NASDAQ:APEN

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Bioventus NYSE:BVS

$6.44 +0.14 (+2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$6.44 -0.01 (-0.08%)

As of 04:20 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$4.30 -0.01 (-0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 0.00 (-0.12%)

As of 04:24 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem NYSE:INFU

$5.75 +0.24 (+4.36%)

Closing price 04:00 PM Eastern

Extended Trading

$5.76 +0.00 (+0.09%)

As of 04:04 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time